U-Systems’ somo •v Automated Breast Ultrasound (ABUS) system is approved for use in combination with mammography for women with dense breast tissue.
The FDA has approved an automated breast ultrasound system for use in combination with mammography for women with dense breast tissue.
U-Systems’ somo•v Automated Breast Ultrasound (ABUS) system is the only approved ultrasound device designed especially for screening women with dense breast tissue who have negative mammograms and no symptoms of disease, the FDA said. These women must also have no previous history of clinical breast intervention.
Ultrasound breast imaging uses a transducer to direct high-frequency sound waves throughout the breast. The uniquely-shaped somo•v Automated Breast Ultrasound system transducer scans the entire breast in approximately one minute and produces several images.
The FDA reviewed clinical study results that asked board-certified radiologists to analyze mammograms alone or along with somo•v ABUS images. The agency reviewed image interpretations from 200 women with dense breasts and negative mammograms.
Masses detected through somo•v ABUS were biopsied, and results revealed a statistically significant increase in breast cancer detection when ABUS images are analyzed alongside mammograms.
Included in the device’s approval, the agency is mandating U-Systems properly train physicians and technologists in using the ABUS transducer, as well as provide each facility with a manual that details the system tests necessary for initial, periodic, and yearly quality-control measures.
Previous research published in the journal European Radiology revealed breast cancer detection doubled among study participants when ABUS was used with mammography. Detection rates also tripled for cancers smaller than 10 mm.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.